Recent News

• 09.08.2025 - Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025
• 08.05.2025 - Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1
• 07.30.2025 - Immutep Quarterly Activities Report Q4 FY25
• 07.29.2025 - Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
• 07.28.2025 - Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
• 06.23.2025 - Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases
• 05.27.2025 - Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
• 05.15.2025 - Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

Recent Filings

• 09.03.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.03.2025 - EX-99.1 EX-99.1
• 08.07.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 08.07.2025 - EX-99.1 EX-99.1
• 07.31.2025 - EX-99.1 EX-99.1
• 07.31.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.24.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.24.2025 - EX-99.1 EX-99.1
• 05.28.2025 - EX-99.1 EX-99.1
• 05.28.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]